Thrombospondins (TSPs) are secreted multimeric glycoproteins that modulate extracellular matrix structure and cell behaviour. TSPs are involved in platelet aggregation, cell adhesion, migration, angiogenesis, wound healing, and proliferation. The purpose of this study was to investigate the function of TSP-2 on the invasion and migration of CT-26, and to determine the domain that is responsible for these functions. The antisense cDNA of TSP-2 was transfected to CT-26 (CT-26/AS-pREP4), which underexpressed TSP-2. Reduction of TSP-2 expression resulted in decreased activity, and decreased expression of the plasminogen/plasmin system. All of which resulted in decreased invasion and migration in vitro. The panels of murine TSP-2 cDNA subunits in CT-26/AS-pREP4 were established. The transfectants containing type 3 repeats domain revealed an increased in vitro invasion and migration, and increased pulmonary metastasis when inoculated into the tail vein of a syngenic mouse. The type 3 repeats domain was both integrin αvβ3 and phosphatidylinositol (PI) 3-kinase/Akt dependent. These findings may be useful for the development of therapeutic interventions that block either integrin αvβ3 or PI 3-kinase dependent Akt phosphorylation, resulting in the reduction of plasminogen/plasmin system and consequently block cell invasion, migration, and metastatic spread of colon cancer cells.
Introduction
Colorectal cancer is a fatal malignancy in the United States; and its incidence is increasing in Korea. 1 Advancedstage colorectal cancer may metastasize to distant sites, which most commonly involves the liver. Once the cancer spreads to distant sites, there is no effective treatment. TSP-2 is a calcium-sensitive, disulfide-bonded trimer. 4 TSPs are involved in platelet aggregation, cell adhesion, migration, angiogenesis, wound healing, and proliferation. 3 TSP-1 and TSP-2 have been identified as anti-angiogenic and anti-proliferative. 5 However there are controversies on the effect of TSP-1 and TSP-2 in tumor metastasis.
Treatment of TSP-1-null mice with recombinant proteins that contain the type-1 repeats of TSP-1 resulted in increased metastasis of breast cancer. 6 TSP-1 was associated with increased tumor cell invasion through a transforming growth factor beta-1, urokinase-type plasminogen activator (uPA), urokinase-type plasminogen activator receptor (uPAR), and plasminogen activator inhibitor type 1 (PAI-1)
in in vitro studies of breast cancer, 7, 8 pancreatic cancer, 9 and lung cancer. 10 The migration of cancer cells induced by TSP-1 was inhibited by an TSP antibody 8, 10 and antibody to the C-terminal domain of TSP-1. 11 These findings support the pro-metastatic property of TSP-1. However, TSP-2 was under-expressed in supraglottic squamous cell carcinomas with lymph node metastases compared with those without lymph node metastases. 12 In the isogenic model of spontaneous human breast cancer metastasis, high expression of TSP-1 was associated with non-metastatic phenotype. 13 Transfection of TSP-1 cDNA into a human breast carcinoma cell line, MDA-MB-435 reduced pulmonary metastatic potential of the cancer.
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The objective of this study was to investigate the activity of TSP-2 in invasion and migration of CT-26, and to determine the subunit(s) of TSP-2 responsible for invasion and migration. In addition, we investigated the signal transduction pathway of TSP-2 involved in increased invasion and migration. We found that X of TSP-2 is associated with increased invasion and migration both in vitro and in vivo. In addition, the function of X was both integrin αvβ3 and phosphatidylinositol (PI) 3-kinase/Akt dependent.
Furthermore, X increased the invasion and migration through over-expression of the urinary plasminogen activator (uPA), urokinase-type plasminogen activator receptor (uPAR) and plasminogen activator inhibitor -1 (PAI-1).
Materials and Methods
Construction of vectors
The cDNA subunits of murine TSP-2 (mTSP-2) were amplified from RNA of CT-26 by RT-PCR with synthetic primers (Fig. 1 , Table 1 ). To amplify the insert of antisense The upper case letters represent the mTSP-2 cDNA sequence or its complementary sequence according to NM_011581. For amplifying AS, the forward primer contained a site for KpnI endonuclease (lower case letters) in addition to the 23 bases of the mTSP-2 cDNA and the reverse primer contained a NotI endonuclease site (lower case letters)and bases complementary to the mTSP-2 cDNA. Nomenclature: AS, antisense; N, N-terminal; O, oligomerisation sequence; P, procollagen module; T, type 1repeats; E, EGF-like; X, type 3 repeats; C, C-terminal globule. expression vectors. They were designated as N-pcDNA3.1, OP-pcDNA3.1, T-pcDNA3.1, E-pcDNA3.1, X-pcDNA3.1, C-pcDNA3.1, NOPTE-pcDNA3.1, and NOPTEX-pcDNA3.1.
The DNA sequences of the constructs were confirmed by sequencing. The constructed vectors used for transfection were purified using affinity columns (Qiagen, Hilden, Germany) according to the manufacturer's instruction. clones from each group were used for further study.
Recombinant X protein (r-X) of mTSP-2
The pDEST17-X plasmid encoding 6×His-X was constructed by Gateway Technology (Invitrogen) using pEntr3C-X, which was constructed by insertion of EcoRI and XhoI double-digested fragment of X-pcDNA3.1 into the pEntr3C vector (Invitrogen). The 6×His-X protein was expressed in E. coli BL21 (DE3) cells, and was affinity-purified using a nickel-containing affinity column, according to the manufacturer's recommendation (Novagen, Madison, WI) (Fig. 2) . The eluted protein was dialyzed against phosphatebuffered saline, and the protein concentration was determined using the Bradford reagent (Bio-Rad, Hercules, CA).
Western blot analysis
The cells were grown to 80% confluence, and whole cell extracts were prepared in lysis buffer [50 mM TrisHCl (pH 7.5), 150 mM NaCl, 1% NP-40, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 μg/ml leupeptin, 
Serumless conditioned media
Cells (1×10 5 ) were grown in 60-mm plates until they were subconfluent, and then were washed three times with ice-cold phosphate buffered saline. One ml of serum-free medium was added to each plate, and the cells were incubated at 37 o C. The conditioned media were collected at 72 hr, and clarified by centrifugation.
The proteins from each conditioned medium were assessed by the Bradford assay.
Casein/plasminogen zymography
For the determination of the plasminogen activators, whole cell extracts were analyzed on 10% SDS polyacrylamide gels containing 1 mg/ml α-casein (Sigma) and 10 μg/ml plasminogen (Calbiochem). After electrophoresis, gels were incubated overnight at room temperature in 100 mM glycine buffer with 5 mM EDTA at pH 8.0. Caseinolytic activity resulting from plasminogen activation was noted by white lysis zones after gel staining with G250 Coomassie brilliant blue. 15 
In vitro invasion and migration assays
In vitro invasion assay was performed using a Transwell chamber and 8 μm pore size polycarbonate membranes migration assays was identical to that used for the in vitro invasion assays with the exception that the 8 μm pore size polycarbonate membranes were not coated with ECM.
In vivo pulmonary metastasis assay
The with a 26-gauge needle. 16 On 14th day after tail vein injection, the animals were sacrificed by cervical dislocation.
The lungs were excised en bloc, and were immersed in 10% buffered formalin. The lung weight was measured, and the number of surface pulmonary nodules was counted under the dissecting microscope. The lung tissue was processed for histological examination.
Statistical analysis
Difference between groups was tested for statistical significance using Kruskal-Wallis test and Mann-Whitney U-test. A p＜0.05 was considered statistically significant. (Fig. 3A) and serumless conditioned media (Fig. 3B) , respectively. The CT-26/AS-pREP4 revealed lower gelatinolytic activity (Fig. 3C) , and decreased expression of uPA, uPAR, and PAI-1 than CT-26/pREP4 (Fig. 3D) . Down-regulation of TSP-2 in CT-26/ASpREP4 was associated with the decreased activity of uPA, and the decreased expression of uPA, uPAR, and PAI-1.
The X of TSP-2 is associated with increased uPA expression, uPA activity, in vitro invasion, and in vitro migration of CT-26/AS-pREP4
The uPA expression was slightly changed in CT-26/ Fig. 4A) . The uPA activity measured by casein/ plasminogen zymography revealed a similar pattern as western blot (Fig. 4B) . The findings suggested that the X might be associated with the uPA expression and activity.
The in vitro invasion of CT-26/ AS-pREP4 and CT-26/ASpREP4/NOPTE-1 was significantly lower than that of CT-26/ pREP4. In addition, invasion of CT-26/AS-pREP4/NO-PTEX-2 and CT-26/AS-pREP4/ X-2 was significantly higher than that of CT-26/AS-pREP4 and CT-26/AS-pREP4/ NOPTE-1, and was as high as that of CT-26/pREP4. The in vitro migration assay disclosed the similar trend as in vitro invasion assay (Fig. 4C, D) . The findings indicated that the X was associated with increased in vitro invasion and migration of CT-26/ AS-pREP4. 60 min of r-X (0.02 μg/ml) treatment until 240 min.
When we added either anti-integrin αvβ3 antibody (20 μg/ml) or LY294002 (50 μM) prior to r-X (0.02 μg/ml) treatment, the uPA level remained unaltered until 240 min. However, pretreatment of PD98059 (50 μM) prior to r-X (0.02 μg/ml) treatment could not block the effect of r-X on the uPA level (Fig. 5C ). The effect of r-X (0.02 μg/ml) on the uPAR and PAI-1 expression was similar as that on uPA (Fig. 5D, E) . The results indicated that the X induced up-regulation of the plasminogen/plasmin system through integrin αvβ3 and PI 3-kinase/Akt pathway.
The X of TSP-2 induced in vitro invasion and migration is integrin αvβ3 and PI 3-kinase/Akt dependent
In vitro invasion of CT-26/AS-pREP4 was increased more than twofold when r-X (0.02 μg/ml) was added.
However addition of either anti-integrin αvβ3 antibody (20 μg/ml) or LY294002 (50 μM) prior to r-X treatment significantly decreased invasion of CT-26/AS-pREP4 compared to r-X (0.02 μg/ml) only treatment. However PD98059 (50 μM) application prior to r-X (0.02 μg/ml) treatment did not block the effect of r-X (Fig. 6A) . The in vitro migration assay revealed a similar tendency as the in vitro invasion assay (Fig. 6B) . This finding displayed a key role for the PI 3-kinase/Akt pathway in the X induced in vitro invasion and migration.
Transfectants containing X reveals increased pulmonary metastasis
In order to verify that transfection of the X increased metastasis of CT-26/AS-pREP4, we inoculated the trans- platelet aggregation, 20 and phagocytosis. 21 Our data show that the effect of the X on invasion and migration is integrin αvβ3 dependent. Moreover, pretreatment of these cells with anti-αvβ3 integrin antibody followed by treatment with r-X suppressed the Akt phosphorylation. This suggests that upregulation of X induces the PI 3-kinase/Akt activity through the αvβ3 integrin-mediated pathway. The X of TSP-1 and TSP-2 orthologues, contains a conserved RGD sequence, the integrin-binding motif. 22 Binding of the RGD sequence with integrin αvβ3, mediates the adhesion of platelets 23 and chemotaxis in human vascular smooth muscle cells. The plasminogen/plasmin system is one of the main protease systems involved in cancer progression. After binding to uPAR, uPA is activated and subsequently converts plasminogen to plasmin. uPA catalyzes the conversion of the inactive zymogen plasminogen to the active broad-spectrum plasmin. This will then degrade a number of matrix proteins and activate other proteases, including some matrix metalloproteinases. 27 It has been
shown that adhesion and invasion of carcinoma cells are potentiated by TSP-1 or -2 through a mechanism involving the plasminogen activator system. This activity is due to the TSP-1 or -2-mediated up-regulation of uPA, uPAR and PAI-1. 7, 8, 10 In addition to increased invasion and migration, TSP-1 and -2 inhibit angiogenesis and tumor growth in a variety of tumors. 28 The anti-angiogenetic activity of TSP-1 has been mapped to TSP type 1 repeats, 29 and interaction of TSP type 1 repeats with CD36 has been implicated also. 30 In 
